NasdaqGM - Delayed Quote USD

Harvard Bioscience, Inc. (HBIO)

3.3700 -0.0700 (-2.03%)
At close: May 17 at 4:00 PM EDT
3.3700 0.00 (0.00%)
After hours: May 17 at 4:02 PM EDT
Loading Chart for HBIO
DELL
  • Previous Close 3.4400
  • Open 3.4600
  • Bid 3.3600 x 100
  • Ask 3.4200 x 100
  • Day's Range 3.3500 - 3.4600
  • 52 Week Range 3.3300 - 6.2000
  • Volume 55,429
  • Avg. Volume 91,331
  • Market Cap (intraday) 146.358M
  • Beta (5Y Monthly) 1.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2000
  • Earnings Date Aug 6, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.92

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

www.harvardbioscience.com

391

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HBIO

Performance Overview: HBIO

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HBIO
37.01%
S&P 500
11.18%

1-Year Return

HBIO
37.94%
S&P 500
29.04%

3-Year Return

HBIO
51.93%
S&P 500
27.06%

5-Year Return

HBIO
42.19%
S&P 500
84.38%

Compare To: HBIO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HBIO

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    146.36M

  • Enterprise Value

    183.47M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.35

  • Price/Book (mrq)

    2.13

  • Enterprise Value/Revenue

    1.72

  • Enterprise Value/EBITDA

    84.20

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -8.18%

  • Return on Assets (ttm)

    -0.69%

  • Return on Equity (ttm)

    -12.20%

  • Revenue (ttm)

    106.79M

  • Net Income Avi to Common (ttm)

    -8.73M

  • Diluted EPS (ttm)

    -0.2000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.25M

  • Total Debt/Equity (mrq)

    60.11%

  • Levered Free Cash Flow (ttm)

    13.77M

Research Analysis: HBIO

Company Insights: HBIO

Research Reports: HBIO

People Also Watch